GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelluna ASA (OSTO:ULTIo) » Definitions » EV-to-EBITDA

Zelluna ASA (OSTO:ULTIO) EV-to-EBITDA : -0.65 (As of Jun. 27, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Zelluna ASA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zelluna ASA's enterprise value is kr138.24 Mil. Zelluna ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr-214.20 Mil. Therefore, Zelluna ASA's EV-to-EBITDA for today is -0.65.

The historical rank and industry rank for Zelluna ASA's EV-to-EBITDA or its related term are showing as below:

OSTO:ULTIo' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.67   Med: 0   Max: 0
Current: -0.64

OSTO:ULTIo's EV-to-EBITDA is ranked worse than
100% of 481 companies
in the Biotechnology industry
Industry Median: 8.87 vs OSTO:ULTIo: -0.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-27), Zelluna ASA's stock price is kr21.95. Zelluna ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-56.000. Therefore, Zelluna ASA's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Zelluna ASA EV-to-EBITDA Historical Data

The historical data trend for Zelluna ASA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelluna ASA EV-to-EBITDA Chart

Zelluna ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.48 -20.41 -18.59 -18.61 0.17

Zelluna ASA Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.64 0.44 0.17 -1.12

Competitive Comparison of Zelluna ASA's EV-to-EBITDA

For the Biotechnology subindustry, Zelluna ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelluna ASA's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's EV-to-EBITDA falls into.


;
;

Zelluna ASA EV-to-EBITDA Calculation

Zelluna ASA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=138.236/-214.196
=-0.65

Zelluna ASA's current Enterprise Value is kr138.24 Mil.
Zelluna ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-214.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zelluna ASA  (OSTO:ULTIo) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Zelluna ASA's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21.95/-56.000
=At Loss

Zelluna ASA's share price for today is kr21.95.
Zelluna ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-56.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Zelluna ASA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zelluna ASA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelluna ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the development of T-Cell Receptor Natural Killer cell therapies for the treatment of solid cancers. The company's current pipeline consists of allogeneic TCR-NK R&D programs ZI-MA4-1, ZI-KL1-1, and ZI-PR-1 targeting well validated antigens expressed across a broad range of solid tumors.

Zelluna ASA Headlines

No Headlines